Xtl Biopharmaceuticals annual free cash flow
2015
2016
2019
2020
2024
Xtl Biopharmaceuticals Free Cash Flow (FCF) History (XTLB)
Xtl Biopharmaceuticals reported −$1.7M in free cash flow for fiscal 2024, a decrease of $821,000 from the previous fiscal year, with a free cash flow margin of −370.73%.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$1.7M | −$821,000 | — | −370.73% |
| 2020 | 2020-12-31 | −$851,000 | $59,000 | — | — |
| 2019 | 2019-12-31 | −$910,000 | $824,000 | — | — |
| 2016 | 2016-12-31 | −$1.7M | $129,000 | — | — |
| 2015 | 2015-12-31 | −$1.9M | — | — | — |
Xtl Biopharmaceuticals quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Xtl Biopharmaceuticals free cash flow growth trends
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Xtl Biopharmaceuticals filings at SEC.gov ↗